http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Nov 2025 12:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Press+Releases/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html <p align="center"><b>OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel </b><br/><b>“Cis-Demasking” Cytokine Technology to Increase </b><br/><b>Therapeutic Index of Immunocytokines </b></p> <p align="justify"><b><br/>NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</b>, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster   on its novel OSE-Cytomask® Cis-Demasking1 immunocytokine technology at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, in National Harbor, Maryland.</p> <p align="justify">OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics http://www.streetinsider.com/Globe+Newswire/OSE+Immunotherapeutics+Presents+a+Poster+on+OSE-Cytomask%C2%AE%2C+a+Novel+%E2%80%9CCis-Demasking%E2%80%9D+Cytokine+Technology+to+Increase+Therapeutic+Index+of+Immunocytokines/25577041.html Fri, 07 Nov 2025 12:00:00 -0500 A.30928927 O.01678312 O.41712658 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html <p>OSE Immunotherapeutics (Euronext: OSE) announced the termination of Nicolas Poirier as chief executive officer and the appointment of Marc Le Bozec as interim CEO, effective immediately following a board decision.</p> <p>The biotech company's board of directors has initiated a formal search for a permanent chief executive officer. Le Bozec will lead a strategic evaluation of OSE's business operations, focusing on partnerships, finances, and clinical development programs.</p> <p>Poirier will retain his position as chief scientific officer at the company. His termination as CEO will not result in any compensation or indemnity payments, as he is remunerated exclusively under his employment contract with OSE.</p> <p>Le http://www.streetinsider.com/Management+Changes/OSE+Immunotherapeutics+names+Marc+Le+Bozec+as+interim+CEO/25415319.html Fri, 03 Oct 2025 02:00:25 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Press+Releases/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE http://www.streetinsider.com/Globe+Newswire/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html <p align="center"><strong>Appointment of Marc Le Bozec as Interim CEO </strong></p> <p align="justify"><strong>Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)</strong> announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.</p> <p align="justify">The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.</p> <p align="justify">The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE&apos;s business, with http://www.streetinsider.com/Globe+Newswire/Appointment+of+Marc+Le+Bozec+as+Interim+CEO/25415318.html Fri, 03 Oct 2025 02:00:00 -0500 A.05542005 A.33162137 A.42701208 O.00819835 O.00832225 O.01234189 O.01678312 OSE